Cargando…
Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review
BACKGROUND: Infections are among the main causes of death in patients with demyelinating diseases of the central nervous system (CNSDD). Vaccines are effective methods in reducing hospitalization and death from infectious diseases, but they are challenging in patients with CNSDD because of autoimmun...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academia Brasileira de Neurologia - ABNEURO
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491426/ https://www.ncbi.nlm.nih.gov/pubmed/35976311 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S121 |
_version_ | 1784793275297693696 |
---|---|
author | Silva, Guilherme Diogo de Oliveira, Vítor Falcão Mendonça, Leonardo Oliveira |
author_facet | Silva, Guilherme Diogo de Oliveira, Vítor Falcão Mendonça, Leonardo Oliveira |
author_sort | Silva, Guilherme Diogo |
collection | PubMed |
description | BACKGROUND: Infections are among the main causes of death in patients with demyelinating diseases of the central nervous system (CNSDD). Vaccines are effective methods in reducing hospitalization and death from infectious diseases, but they are challenging in patients with CNSDD because of autoimmunity and immunosuppression. OBJECTIVES: To summarize the pathophysiological rationale and main evidence for vaccine recommendations in patients with CNSDD. METHODS: Specialists with different backgrounds on the subject: a neurologist specialized in demyelinating diseases, an infectious diseases specialist and an immunologist, presented a critical narrative review of vaccination literature in patients with CNSDD, highlighting which vaccines should or should not be administered and the best time for it. RESULTS: Patients with DDSNC are at increased risk of vaccine-preventable viral and bacterial infections. Vaccines can prevent herpes zoster, hepatitis B reactivation, HPV-associated warts and tumors, viral and bacterial pneumonia, and meningitis. Live attenuated virus vaccines should not be used when the patient is on immunosuppression. Vaccines should be avoided during relapses. The greatest vaccine efficacy is given before treatment or at the end of medication. CONCLUSION: Patients with DDSNC need differentiated immunization in relation to additional vaccines, contraindicated vaccines and timing of vaccination. |
format | Online Article Text |
id | pubmed-9491426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Academia Brasileira de Neurologia - ABNEURO |
record_format | MEDLINE/PubMed |
spelling | pubmed-94914262022-12-08 Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review Silva, Guilherme Diogo de Oliveira, Vítor Falcão Mendonça, Leonardo Oliveira Arq Neuropsiquiatr Inflammatory and Demyelinating Disease BACKGROUND: Infections are among the main causes of death in patients with demyelinating diseases of the central nervous system (CNSDD). Vaccines are effective methods in reducing hospitalization and death from infectious diseases, but they are challenging in patients with CNSDD because of autoimmunity and immunosuppression. OBJECTIVES: To summarize the pathophysiological rationale and main evidence for vaccine recommendations in patients with CNSDD. METHODS: Specialists with different backgrounds on the subject: a neurologist specialized in demyelinating diseases, an infectious diseases specialist and an immunologist, presented a critical narrative review of vaccination literature in patients with CNSDD, highlighting which vaccines should or should not be administered and the best time for it. RESULTS: Patients with DDSNC are at increased risk of vaccine-preventable viral and bacterial infections. Vaccines can prevent herpes zoster, hepatitis B reactivation, HPV-associated warts and tumors, viral and bacterial pneumonia, and meningitis. Live attenuated virus vaccines should not be used when the patient is on immunosuppression. Vaccines should be avoided during relapses. The greatest vaccine efficacy is given before treatment or at the end of medication. CONCLUSION: Patients with DDSNC need differentiated immunization in relation to additional vaccines, contraindicated vaccines and timing of vaccination. Academia Brasileira de Neurologia - ABNEURO 2022-08-12 /pmc/articles/PMC9491426/ /pubmed/35976311 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S121 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License |
spellingShingle | Inflammatory and Demyelinating Disease Silva, Guilherme Diogo de Oliveira, Vítor Falcão Mendonça, Leonardo Oliveira Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review |
title | Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review |
title_full | Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review |
title_fullStr | Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review |
title_full_unstemmed | Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review |
title_short | Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review |
title_sort | challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review |
topic | Inflammatory and Demyelinating Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491426/ https://www.ncbi.nlm.nih.gov/pubmed/35976311 http://dx.doi.org/10.1590/0004-282X-ANP-2022-S121 |
work_keys_str_mv | AT silvaguilhermediogo challengesandinsightsinimmunizationinpatientswithdemyelinatingdiseasesabenchtobedsideandevidencebasedreview AT deoliveiravitorfalcao challengesandinsightsinimmunizationinpatientswithdemyelinatingdiseasesabenchtobedsideandevidencebasedreview AT mendoncaleonardooliveira challengesandinsightsinimmunizationinpatientswithdemyelinatingdiseasesabenchtobedsideandevidencebasedreview |